Olle from Sweden

Registered at the short selling broker Skilling, 4 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Eli Lilly & Co. (LLY) stock information

Eli Lilly & Co.

24h Change

-0.74 %

LLY

Live rate: Market closed

Stock data per Friday 22 May, 2020

LLY
New York Stock Exchange
152.28
152.22
151.16
-1.12 (-0.74%)
US Market is closed

Live Stock price in graph for Eli Lilly & Co. (LLY)

Data updated continously for LLY, showing up to the 500 most recent 100 data points

  • Latest Volume

    2,354,972 (-22.78 %)

  • Volume prev. day

    3,049,756

  • Avg. daily volume

    3,086,912

  • Market cap

    144,665,864,080

  • P/E ratio

    24.98

  • Today high

    152.56

  • Today low

    150.167

  • 52 week high

    164.9

  • 52 week low

    101.36

  • YTD Change

    + 13.99 %

 

Latest news about Eli Lilly & Co.

Below you can find the most recent news posts about Eli Lilly & Co., primarily from US and UK based news sources.

Research Report with COVID-19 Forecasts – Post-traumatic Stress Disorder Therapeutics Market 2020-2024 | Rising Prevalence of PTSD to Boost Growth | Technavio

Monday, 25 May 2020, 20:30:00
Technavio has been monitoring the post-traumatic stress disorder therapeutics market and it is poised to grow by USD 909.86 million during 2020-2024, progressing at a CAGR of over 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200525005262/en/ Technavio has announced its latest market research report titled Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2020-2024 (Graphic: Business Wire) Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H.
— Benzinga Feeds


Outlook on the Global Diabetes Disposable Insulin Delivery Pen Industry to 2026 – Major Players Analysed are Novo Nordisk, Eli Lilly & Sanofi Among Others – ResearchAndMarkets.com

Friday, 22 May 2020, 11:42:00
DUBLIN–(BUSINESS WIRE)–The “Worldwide Diabetes Disposable Insulin Delivery Pen Market Prospect, Share, Development, Growth & Demand Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering. The Worldwide Diabetes Disposable Insulin Delivery Pen Market size is anticipated to exceed USD 14 billion by 2026. The objective of this market research report is to provide a comprehensive analysis of the fast-evolving, high-growth worldwide diabetes disposable insulin delivery pe
— Business Wire


Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold

Friday, 15 May 2020, 18:08:00
Zacks.com featured highlights include: Clorox, Sprouts Farmers, Eli Lilly, Gold Fields and AngloGold
— Zacks Investment Research


Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY

Friday, 15 May 2020, 14:45:00
FDA approves Lilly’s (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck’s (MRK) Lynparza for new ovarian cancer use.
— Zacks Investment Research


Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020

Wednesday, 13 May 2020, 21:00:00
INDIANAPOLIS, May 13, 2020 /PRNewswire/ — Data from 23 studies across Eli Lilly and Company’s (NYSE: LLY) oncology product portfolio will be presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO), held virtually, May 29-31, 2020. The data, which include…
— PR Newswire